Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
15/06/2026 14:12
BRIEF-Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis June 15 (Reuters) - XBiotech Inc XBIT.O:
XBIOTECH LAUNCHES PHASE II CLINICAL TRIAL EVALUATING VILAMAKITUG FOR THE TREATMENT OF ACTIVE AXIAL SPONDYLOARTHRITIS
XBIOTECH - IND APPLICATION FOR V-SPINE COMPLETES FDA REVIEW WITH NO CLINICAL HOLD
Source text: ID:nGNXbMtn1q
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke